论文部分内容阅读
目的评价依折麦布与他汀类联合用药与他汀类单独用药的成本-效果。方法收集DYSIS-CHINA研究人群中,采用中大剂量他汀类药物治疗至少3个月后血脂水平仍不达标的患者,运用Markov模型模拟预测其未来一定时间内发生心血管事件情况及医疗费用。结果经过6周降脂治疗,依折麦布与他汀类联合用药比他汀单药剂量加倍可减少未来10年内非致命性冠心病、非致命性卒中、心脑血管疾病病死的发生,并降低医疗费用。结论依折麦布与他汀类联合用药比他汀单药剂量加倍具有更好的成本-效果。
Objective To evaluate the cost-effectiveness of ezetimibe plus statins and statins alone. Methods The patients in DYSIS-CHINA study population who were treated with medium and large doses of statins for at least 3 months and who still did not meet their lipid levels were enrolled. The Markov model was used to predict the occurrence of cardiovascular events and medical expenses in a certain period in the future. Results After 6 weeks of lipid-lowering treatment, the combination of ezetimibe and statins double the dose of statin alone can reduce the incidence of non-fatal coronary heart disease, non-fatal stroke, cardiovascular and cerebrovascular diseases in the next 10 years and reduce the incidence of medical treatment cost. Conclusions Ezetimibe and statin combinations have a better cost-effectiveness than single doses of statins.